Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flecainide for motor neuron disease
ACTRN12608000338369Phase 2Recruiting
- Sponsor
- South Eastern Sydney Illawarra Area Health Service
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in motor neuron disease (MND) and amyotrophic lateral sclerosis (ALS) comparing Flecainide with Placebo (2 arms). Primary endpoint: Rate of change in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised at week 44. Started Mar 2008; status: recruiting.
02
Drugs
flecainide
03
Conditions
motor neuron disease (MND)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ACTRN12608000338369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000338369.